Vardenafil: An oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction

anagrelide and vardenafil both increase QTc interval. apalutamideapalutamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed. apalutamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether and vardenafil both increase QTc interval.

• Vardenafil is a medication used to treat erectile dysfunction.
• It belongs to the class of PDE5 inhibitors.
• Typical adult dosage ranges from 5 to 20 mg.
• It is usually taken 30 to 60 minutes before activity.
• The medication's effects can last up to 4-6 hours.
• Vardenafil may cause side effects like headache or flushing.
• Alcohol consumption can increase side effects risk.
• It should not be used with nitrate drugs.
• Vardenafil is available by prescription only.
• It may interact with certain medications such as alpha-blockers.
• Proper dosing depends on medical history and response.

asenapineasenapine and vardenafil both increase QTc interval. asenapine and vardenafil both increase QTc interval. asenapine transdermalasenapine transdermal and vardenafil both increase QTc interval.

1. Background of Erectile Dysfunction and Need for Alternative Formulations

nitroglycerin rectalvardenafil increases effects of nitroglycerin rectal by additive vasodilation. Use of nitroglycerin within a few days of PDE5 inhibitors is contraindicated. PDE5 inhibitors have been shown to potentiate the hypotensive effects of organic nitrates. vardenafil increases effects of nitroglycerin rectal by additive vasodilation. Either increases effects of the other by additive vasodilation.

Platelet-rich plasma intracavernosal injections for the treatment of primary organic erectile dysfunction: a systematic review and meta-analysis of contemporary controlled studies

Coadministration of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil) and guanylate cyclase stimulators (eg, riociguat) is contraindicated tadalis oral jelly due to risk of additive hypotension. Either increases effects of the other by pharmacodynamic synergism. Coadministration of vericiguat with PDE-5 inhibitors may result in additive hypotensive effects. Either increases effects of the other by QTc interval. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. asenapine transdermal and vardenafil both increase QTc interval. Either increases effects of the other by Other (see comment). Comment: Avoid combination; duplicate therapy is not recommended. buprenorphinebuprenorphine and vardenafil both increase QTc interval.

buprenorphine and vardenafil both increase QTc interval. buprenorphine buccalbuprenorphine buccal and vardenafil both increase QTc interval. buprenorphine buccal and vardenafil both increase QTc interval. buprenorphine subdermal implantbuprenorphine subdermal implant and vardenafil both increase QTc interval. buprenorphine subdermal implant and vardenafil both increase QTc interval. buprenorphine transdermalbuprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine, long-acting injectionbuprenorphine, long-acting injection and vardenafil both increase QTc interval. buprenorphine, long-acting injection and vardenafil both increase QTc interval. carbamazepinecarbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. carbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinib and vardenafil both increase QTc interval. clarithromycinclarithromycin and vardenafil both increase QTc interval. clarithromycin and vardenafil both increase QTc interval. danazoldanazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. danazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

LinkOut - more resources

Furthermore, coprecipitated-dispersed mixtures of vardenafil and three sweeteners (sorbitol, acesulfame K, and sucralose) were prepared and characterized using FTIR, DSC, and solubility studies. Moreover, eight different vardenafil ODFs were prepared using the solvent-casting method. Modified gustatory sensation test, in vitro disintegration, and release studies were performed. In addition, the optimized ODF (F8) was compared with the commercial film-coated tablets pharmacokinetically (relative bioavailability, onset, and duration of actions were estimated). The results indicated that the three sweetening agents had comparable solubilizing capacity.

Some side effects can be serious. If you experience any of the following symptoms , call your doctor immediately:

However, both sucralose- and acesulfame K-based ODFs have a more enhanced sweet and palatable taste than sorbitol-sweetened ODF. The SA- and PVP K30-based ODFs showed significantly faster disintegration times and release rates than MC. In conclusion, PVA has good film-forming properties, but a higher ratio of PVA adversely affected the disintegration and release characteristics. The % relative bioavailability for ODF was 126.5%, with a superior absorption rate constant (Ka) of 1.2-fold. The Cmax and estimated Tmax were compared to conventional film-coated tablets.

Other Literature Sources

The authors declare no conflict of interest. EAU on erectile dysfunction, premature ejaculation, penile curvature and priapism. 10 mg PO ~1 hour before sexual activity; may be increased to 20 mg or reduced to 5 mg, depending on effectiveness and tolerance; not to exceed 1 dose/day TabletKetoconazole 200 mg/day or itraconazole 200 mg/day: Vardenafil dosage not to exceed 5 mg/dayIndinavir, saquinavir, atazanavir, clarithromycin, ketoconazole 400 mg/day or itraconazole 400 mg/day: Vardenafil dosage not to exceed 2.5 mg/dayRitonavir (600 mg q12hr) or cobicistat: Vardenafil dosage not to exceed 2.5 mg/72 hrErythromycin 500 mg q8hr: Vardenafil dosage not to exceed 5 mg/day Ketoconazole 200 mg/day or itraconazole 200 mg/day: Vardenafil dosage not to exceed 5 mg/day Indinavir, saquinavir, atazanavir, clarithromycin, ketoconazole 400 mg/day or itraconazole 400 mg/day: Vardenafil dosage not to exceed 2.5 mg/day Ritonavir (600 mg q12hr) or cobicistat: Vardenafil dosage not to exceed 2.5 mg/72 hr Erythromycin 500 mg q8hr: Vardenafil dosage not to exceed 5 mg/day Oral disintegrating tablet (ODT)Strong or moderate CYP3A4 inhibitors: Do not use (unable to adjust vardenafil dose) Strong or moderate CYP3A4 inhibitors: Do not use (unable to adjust vardenafil dose) Only initiate vardenafil if stabilized on alpha-blocker Stabilized on alpha-blocker therapy (eg, alfuzosin, terazosin, tamsulosin): 5 mg/day PO initially Stabilized on alpha-blocker therapy and taking moderate-to-strong CYP3A4 inhibitor: 2.5 mg/day PO initially Consider time interval between dosing when vardenafil is concomitantly used with alpha-blocker therapy Mild-to-severe: No dosage adjustment necessary Mild (Child-Pugh A): No dosage adjustment necessary Moderate (Child-Pugh B): Start 5mg PO ~1 hr before sexual activity; not to exceed 10 mg once daily Severe (Child-Pugh C): Do not use Mild (Child-Pugh A): No dosage adjustment necessary Moderate-to-severe (Child-Pugh B or C): Do not use Orphan designation for treatment of pulmonary arterial hypertension Respira Therapeutics, Inc; 5901 Indian School Road NE, suite 107; Albuquerque, New Mexico 87110 Film-coated tablet: 10 mg PO ~1 hour before sexual activity; may be increased to 20 mg or reduced to 5 mg, depending on effectiveness and tolerance; not to exceed 1 dose/day Orally disintegrating tablet (ODT): 10 mg PO placed on tongue ~1 hour before sexual activity; not to exceed 1 dose/day; not interchangeable with 10-mg film-coated tablet; if higher or lower doses required, film-coated tablet should be prescribed AUC and Cmax increased by 39% and 21%, respectively, in elderly men (compared with men <45 years) lefamulinlefamulin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval. lefamulin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. doxazosinvardenafil increases effects of doxazosin by pharmacodynamic synergism.

Brand names

Vardenafil hydrochloride matches exactly in strength and form. Lower production costs pass directly to customers. Generic tablets use the same orange round design. Standard shipping takes 5-10 business days. Express options deliver in 2-5 days.

Medications & Supplements

Overnight available domestically in 1-2 days. Yes, all packages use plain boxes with no markings. Accept credit cards, debit cards, PayPal, and cryptocurrency. Bioequivalent to brands with identical active ingredients. Yes, discounts on packs over 30 units.

6.1 Administration Advice

Enjoy no prescription requirements, fast discrete shipping, and guaranteed quality. Place your order today for quick delivery of this reliable medication. Oral, quick response, and on demand, also known as a spontaneous oral treatment for erectile dysfunction, is highly needed by both patients and physicians. Vardenafil is selective (fewer side effects) and more effective in difficult-to-treat conditions than sildenafil. This study aims at fostering the dual objectives of using biomolecules such as artificial sweetening agents to solubilize and mask the bitterness of vardenafil loaded on biodegradable polymeric materials (PVA, MC, SA, and PVP K30) to fabricate oral, fast-dissolving films (vardenafil ODFs) in the mouth without the need for water to ingest the dosage form. vardenafil increases effects of doxazosin by pharmacodynamic synergism. entrectinib and vardenafil both increase QTc interval. eribulin and vardenafil both increase QTc interval.

Side Effects

If coadministration unavoidable, more frequent monitoring is recommended for such patients. alfuzosinvardenafil increases effects of alfuzosin by pharmacodynamic synergism. vardenafil increases effects of alfuzosin by pharmacodynamic synergism. amisulprideamisulpride and vardenafil both increase QTc interval. amisulpride and vardenafil both increase QTc interval. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.

• Vardenafil is a prescription medication for erectile dysfunction.
• It works by relaxing blood vessels in the penis.
• The drug's effectiveness depends on sexual arousal.
• Vardenafil is often taken before planned sexual activity.
• It is not a cure but a temporary solution for ED.
• Patients should inform their doctor of all current medications.
• Report any sudden vision loss or hearing issues promptly.
• Vardenafil's safety profile is well established when used correctly.
• The medication is part of a class of PDE5 inhibitors.
• It is not recommended to combine with recreational drugs.
• Some users report relief within 15-30 minutes of intake.

givinostatvardenafil and givinostat both increase QTc interval.

If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold if QTc interval >500 ms or a change from baseline >60 ms.